A Phase 2b Study for Moderate-to-Severe Atopic Dermatitis This study tests a new treatment called rezpegaldesleukin (Rezpeg) for adults with moderate to severe atopic dermatitis, a skin condition causing itchy, inflamed skin. Participants will receive this treatment in a randomized, double-blind study, meaning neither the participants nor the researchers will know who receives the actual treatment or a placebo until the study ends. The study includes several phases: a screening period of 15-35 days, a 16-week treatment phase, and additional follow-up lasting up to two years. Atopic dermatitis severity is measured using scores like EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), and BSA (Body Surface Area affected by dermatitis). Participants must be adults, have had atopic dermatitis for at least a year, and have tried topical treatments without success. They must also be willing to attend study visits, complete questionnaires, and give informed consent. The study excludes people who have used certain medications, have other interfering skin conditions, are pregnant, or have certain health issues. Key Points:

• Study duration: up to 104 weeks, including follow-up.
• Participants may be compensated for their time.
• Potential risks include side effects from the treatment.